Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC)
Autoři:
Pei Yuan Fong aff001; Sze Huey Tan aff002; Darren Wan Teck Lim aff001; Eng Huat Tan aff001; Quan Sing Ng aff001; Kiattisa Sommat aff003; Daniel Shao Weng Tan aff001; Mei Kim Ang aff001
Působiště autorů:
Division of Medical Oncology, National Cancer Centre, Singapore
aff001; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, Singapore
aff002; Division of Radiation Oncology, National Cancer Centre, Singapore
aff003
Vyšlo v časopise:
PLoS ONE 14(11)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0224665
Souhrn
Aim
Treatment strategies in laryngeal squamous cell cancer (LSCC) straddle the need for long term survival and tumor control as well as preservation of laryngeal function as far as possible. We sought to identify prognostic factors affecting LSCC outcomes in our population.
Methods
Clinical characteristics, treatments and survival outcomes of patients with LSCC were analysed. Baseline comorbidity data was collected and age-adjusted Charlson Comorbidity Index (aCCI) was calculated. Outcomes of overall survival (OS), progression-free survival (PFS) and laryngectomy-free survival (LFS) were evaluated.
Results
Two hundred and fifteen patients were included, 170 (79%) underwent primary radiation/ chemoradiation and the remainder upfront surgery with adjuvant therapy where indicated. The majority of patients were male, Chinese and current/ex-smokers. Presence of comorbidity was common with median aCCI of 3. Median OS was 5.8 years. On multivariable analyses, high aCCI and advanced nodal status were associated with inferior OS (HR 1.24 per one point increase in aCCI, P<0.001 and HR 3.52; p<0.001 respectively), inferior PFS (HR 1.14; p = 0.007 and HR 3.23; p<0.001 respectively) and poorer LFS (HR 1.19; p = 0.001 and HR 2.95; p<0.001 respectively). Higher tumor (T) stage was associated with inferior OS and LFS (HR 1.61; p = 0.02 and HR 1.91; p = 0.01 respectively).
Conclusion
In our Asian population, the presence of comorbidities and high nodal status were associated with inferior OS, PFS and LFS whilst high T stage was associated with inferior LFS and OS.
Klíčová slova:
Oncology – Cancer treatment – Cancer detection and diagnosis – Surgical and invasive medical procedures – Cancer chemotherapy – Radiation therapy – Surgical oncology – Laryngectomy
Zdroje
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–386. doi: 10.1002/ijc.29210 25220842
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Feb;66(1):7–30. doi: 10.3322/caac.21332 26742998
3. Talamini R, Bosetti C, La Vecchia C, Dal Maso L, Levi F, Bidoli E, et al. Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study. Cancer Causes Control CCC. 2002 Dec;13(10):957–64. doi: 10.1023/a:1021944123914 12588092
4. Cosetti M, Yu G-P, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008 Apr;134(4):370–9. doi: 10.1001/archotol.134.4.370 18427002
5. Hartl DM, Brasnu DF. Contemporary Surgical Management of Early Glottic Cancer. Otolaryngol Clin North Am. 2015 Aug;48(4):611–25.
6. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991 13;324(24):1685–90. doi: 10.1056/NEJM199106133242402 2034244
7. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003 Nov 27;349(22):2091–8. doi: 10.1056/NEJMoa031317 14645636
8. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013 Mar 1;31(7):845–52.
9. Soo K-C, Tan E-H, Wee J, Lim D, Tai B-C, Khoo M-L, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8;93(3):279–86. doi: 10.1038/sj.bjc.6602696 16012523
10. Iyer NG, Tan DSW, Tan VKM, Wang W, Hwang J, Tan N-C, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer. 2015 May 15;121(10):1599–607. doi: 10.1002/cncr.29251 25639864
11. Rosenthal DI, Mohamed ASR, Weber RS, Garden AS, Sevak PR, Kies MS, et al. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15;121(10):1608–19. doi: 10.1002/cncr.29241 25586197
12. Grover S, Swisher-McClure S, Mitra N, Li J, Cohen RB, Ahn PH, et al. Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):594–601. doi: 10.1016/j.ijrobp.2015.03.004 26068492
13. Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA, Porubsky ES. The effect of treatment on survival in patients with advanced laryngeal carcinoma. The Laryngoscope. 2009 Jul;119(7):1312–7. doi: 10.1002/lary.20477 19444887
14. Multidisciplinary Larynx Cancer Working Group, Mulcahy CF, Mohamed ASR, Kanwar A, Hutcheson KA, Ghosh A, et al. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018 Sep;40(9):2060–9. doi: 10.1002/hed.25200 29756307
15. Wang JR, Habbous S, Espin-Garcia O, Chen D, Huang SH, Simpson C, et al. Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma. Head Neck. 2016 May;38(5):736–42. doi: 10.1002/hed.23947 25521753
16. Göllnitz I, Inhestern J, Wendt TG, Buentzel J, Esser D, Böger D, et al. Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, Germany. Cancer Med. 2016;5(11):3260–71. doi: 10.1002/cam4.882 27726294
17. Bøje CR, Dalton SO, Grønborg TK, Primdahl H, Kristensen CA, Andersen E, et al. The impact of comorbidity on outcome in 12 623 Danish head and neck cancer patients: a population based study from the DAHANCA database. Acta Oncol Stockh Swed. 2013 Feb;52(2):285–93.
18. Datema FR, Ferrier MB, van der Schroeff MP, Baatenburg de Jong RJ. Impact of comorbidity on short-term mortality and overall survival of head and neck cancer patients. Head Neck. 2010 Jun;32(6):728–36. doi: 10.1002/hed.21245 19827120
19. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol. 2007 Apr;14(4):1449–57. doi: 10.1245/s10434-006-9296-1 17235712
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. doi: 10.1016/0021-9681(87)90171-8 3558716
21. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245–51. doi: 10.1016/0895-4356(94)90129-5 7722560
22. Piccirillo JF. Importance of comorbidity in head and neck cancer. The Laryngoscope. 2000 Apr;110(4):593–602. doi: 10.1097/00005537-200004000-00011 10764003
23. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld RM, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. The Laryngoscope. 1997 Nov;107(11 Pt 1):1469–75. doi: 10.1097/00005537-199711000-00009 9369392
24. Paleri V, Wight RG, Silver CE, Haigentz M, Takes RP, Bradley PJ, et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol. 2010 Oct;46(10):712–9. doi: 10.1016/j.oraloncology.2010.07.008 20850371
25. Chang J-H, Wu C-C, Yuan KS-P, Wu ATH, Wu S-Y. Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget. 2017 Aug 15;8(33):55600–12. doi: 10.18632/oncotarget.16340 28903447
26. Chen AY, Matson LK, Roberts D, Goepfert H. The significance of comorbidity in advanced laryngeal cancer. Head Neck. 2001 Jul;23(7):566–72. doi: 10.1002/hed.1079 11400245
27. Hu M, Ampil F, Clark C, Sonavane K, Caldito G, Nathan C-AO. Comorbid predictors of poor response to chemoradiotherapy for laryngeal squamous cell carcinoma. The Laryngoscope. 2012 Mar;122(3):565–71. doi: 10.1002/lary.22489 22252981
28. Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2004 Mar 15;10(6):1956–62.
29. Mell LK, Dignam JJ, Salama JK, Cohen EEW, Polite BN, Dandekar V, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Jan 1;28(1):15–20.
30. Massa ST, Osazuwa-Peters N, Christopher KM, Arnold LD, Schootman M, Walker RJ, et al. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017;65:8–15. doi: 10.1016/j.oraloncology.2016.12.006 28109473
31. Baxi SS, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. Cancer. 2014 May 15;120(10):1507–13. doi: 10.1002/cncr.28588 24863390
32. Singh B, Bhaya M, Zimbler M, Stern J, Roland JT, Rosenfeld RM, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 1998 Jan;20(1):1–7. doi: 10.1002/(sici)1097-0347(199801)20:1<1::aid-hed1>3.0.co;2-8 9464945
33. Genther DJ, Gourin CG. Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery in the elderly. Head Neck. 2015 May;37(5):685–93. doi: 10.1002/hed.23651 24596299
34. Baijal G, Gupta T, Hotwani C, Laskar SG, Budrukkar A, Murthy V, et al. Impact of comorbidity on therapeutic decision-making in head and neck cancer: audit from a comprehensive cancer center in India. Head Neck. 2012 Sep;34(9):1251–4. doi: 10.1002/hed.21897 22076917
35. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Factors that influence treatment decision in older patients with resectable head and neck cancer. The Laryngoscope. 2007 May;117(5):835–40. doi: 10.1097/MLG.0b013e3180337827 17473679
36. Brandstorp-Boesen J, Sørum Falk R, Boysen M, Brøndbo K. Impact of stage, management and recurrence on survival rates in laryngeal cancer. PloS One. 2017;12(7):e0179371. doi: 10.1371/journal.pone.0179371 28708883
37. Harris BN, Bhuskute AA, Rao S, Farwell DG, Bewley AF. Primary surgery for advanced-stage laryngeal cancer: A stage and subsite-specific survival analysis. Head Neck. 2016;38(9):1380–6. doi: 10.1002/hed.24443 27014858
38. Fuller CD, Mohamed ASR, Garden AS, Gunn GB, Mulcahy CF, Zafereo M, et al. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016;38(12):1739–51. doi: 10.1002/hed.24532 27466789
39. Choi YS, Park SG, Song E-K, Cho S-H, Park M-R, Park KU, et al. Comparison of the therapeutic effects of total laryngectomy and a larynx-preservation approach in patients with T4a laryngeal cancer and thyroid cartilage invasion: A multicenter retrospective review. Head Neck. 2016;38(8):1271–7. doi: 10.1002/hed.24438 27043228
40. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med. 2004 May 6;350(19):1945–52. doi: 10.1056/NEJMoa032641 15128894
41. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2004 May 6;350(19):1937–44. doi: 10.1056/NEJMoa032646 15128893
42. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843–50. doi: 10.1002/hed.20279 16161069
43. Dronkers EAC, Mes SW, Wieringa MH, van der Schroeff MP, Baatenburg de Jong RJ. Noncompliance to guidelines in head and neck cancer treatment; associated factors for both patient and physician. BMC Cancer. 2015 Jul 11;15:515. doi: 10.1186/s12885-015-1523-3 26163015
44. Habbous S, Chu KP, Harland LTG, La Delfa A, Fadhel E, Sun B, et al. Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. Oral Oncol. 2013 May;49(5):407–12. doi: 10.1016/j.oraloncology.2012.11.010 23291295
Článok vyšiel v časopise
PLOS One
2019 Číslo 11
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Je Fuchsova endotelová dystrofie rohovky neurodegenerativní onemocnění?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- A daily diary study on maladaptive daydreaming, mind wandering, and sleep disturbances: Examining within-person and between-persons relations
- A 3’ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction
- A substitution mutation in a conserved domain of mammalian acetate-dependent acetyl CoA synthetase 2 results in destabilized protein and impaired HIF-2 signaling
- Molecular validation of clinical Pantoea isolates identified by MALDI-TOF